Cerebrovascular diseases (Basel, Switzerland) · 2003
Complaints of poststroke insomnia and its treatment with mianserin.
Клиническое исследованиеСравнительное исследованиеОценочное исследованиеСтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Palomäki Heikki, Berg Anu, Meririnne Esa, Kaste Markku, Lönnqvist Riitta, Lehtihalmes Matti, Lönnqvist Jouko
Аннотация
Drospirenone 3mg with ethinylestradiol 20microg (Yaz) is a low-dose combined oral contraceptive (COC) administered in a regimen of 24 days of active tablets followed by a short hormone-free interval (4 days; 24/4 regimen). Drospirenone, unlike other synthetic progestogens used in COCs, is a 17alpha-spirolactone derivative and a 17alpha-spironolactone analogue with antimineralocorticoid and antiandrogenic properties. Drospirenone/ethinylestradiol 3mg/20microg (24/4) is approved in the US for the prevention of pregnancy in women, for the treatment of the symptoms of premenstrual dysphoric disorder (PMDD) and for the treatment of moderate acne vulgaris in women who wish to use an oral contraceptive for contraception.Drospirenone/ethinylestradiol 3mg/20microg (24/4) provided 99% contraceptive protection over 1 year of treatment in two large studies. The same treatment regimen over three treatment cycles also significantly improved the emotional and physical symptoms associated with PMDD, and improved moderate acne vulgaris over six treatment cycles in double-blind trials. It was generally well tolerated, with adverse events generally typical of those experienced with other COCs and which were most likely to occur in the first few cycles. Clinical trials indicate that drospirenone/ethinylestradiol 3mg/20microg (24/4) is a good long-term contraceptive option, and additionally offers relief of symptoms that characterise PMDD and has a favourable effect on moderate acne vulgaris.
Предметные рубрики MeSH
Age FactorsAgedAntidepressive Agents, Second-GenerationDepressionDose-Response Relationship, DrugDouble-Blind MethodFemaleFinlandFollow-Up StudiesHumansMaleMianserinMiddle AgedPatient SatisfactionPredictive Value of TestsPrevalenceQuality of LifeRisk FactorsSeverity of Illness IndexSex FactorsSleep Initiation and Maintenance DisordersStatistics as TopicStrokeTime FactorsTreatment Outcome